Application of RIP3 inhibitor in preparation of pharmaceutical composition for relieving lung transplantation ischemia reperfusion injury
The RIP3 pathway inhibition through GSK'872 solves the problem of programmed necrosis and inflammation caused by ischemia and reperfusion injury in lung transplantation, significantly improves the prognosis after lung transplantation, and provides an effective treatment method for lung transplant complications.
Patent Information
- Application Number
- CN202411427242.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-14
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Ischemia and reperfusion injury after lung transplantation is the main factor leading to primary graft failure and obstructive bronchiolititis syndrome. The prior art has not effectively inhibited RIP3-mediated cell programmed necrosis, affecting the prognosis of lung transplantation.
GSK'872 is used as a RIP3 inhibitor to reduce programmed necrosis and inflammation in the transplanted lung by inhibiting RIP3-dependent lung macrophage inflammation and NLRP3 inflammasome pathways, respectively, and administering drugs at the cold ischemia and reperfusion stages with different mechanisms. Plays a protective role.
It significantly alleviates ischemia-reperfusion injury in lung transplantation in rats, improves lung function after transplantation, and provides new therapeutic strategies to reduce the risk of transplant complications.
Smart Images

Figure CN118924752A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to use of a RIP3 inhibitor in preparing a pharmaceutical composition for alleviating ischemia-reperfusion injury in lung transplantation. Background Art
[0002] Lung transplantation is currently the main effective means of treating end-stage lung disease. Primary graft dysfunction (PGD) is one of the most common and serious complications after lung transplantation, and is closely related to early postoperative death and long-term complications such as bronchiolitis obliterans syndrome (BOS).
[0003] PGD is mainly caused by epithelial and endothelial dysfunction, cell death and microenvironmental changes caused by lung ischemia-reperfusion injury (LIRI) and innate immune response, and is manifested by pulmonary edema, thrombosis and decreased pulmonary oxygenation capacity. Among all the factors that cause PGD, ischemia-reperfusion injury is particularly important, and many studies even regard PGD as a clinical manifestation of lung ischemia-reperfusion injury. Therefore, timely treatment of lung ischemia-reperfusion injury is the key to preventing PGD.
[0004] Recent transcriptomic studies have shown that the enrichment of cell death-related gene clusters in human lung transplant ischemia-reperfusion injury has the most significant impact on the prognosis of lung transplantation. Various programmed cell deaths provide biomarkers and therapeutic targets for lung transplant injury.
[0005] Programmed cell death in LIRI includes apoptosis, programmed cell necrosis, pyroptosis, autophagy, ferroptosis, etc. In the past, researchers paid more attention to alleviating LIRI by inhibiting apoptosis, tissue inflammation, oxidative stress and other pathways. In recent years, the role of various new cell death modes in LIRI has attracted much attention, including ferroptosis and programmed cell necrosis.
[0006] Programmed cell necrosis, also known as necroptosis, was first reported in 2005 and is the most intensively studied type of regulated cell death. It is mediated by the sequential phosphorylation of receptor interacting protein kinase-1 (RIP1), receptor interacting protein kinase-3 (RIP3) and downstream mixed-lineage kinase domain like (MLKL). The phosphorylated MLKL eventually oligomerizes and moves to the cell membrane and punches holes in the cell membrane, leading to cell rupture and death. The interaction between RIP1 and RIP3 to form and activate necrosomes and the phosphorylation of MLKL molecules are considered to be the two key steps of programmed necrosis.
[0007] Currently, researchers have used the RIP1 inhibitor Necrostatin-1 (Nec-1) and the MLKL inhibitor Necrosulfonamide (NSA) to study the role of programmed cell necrosis in LIRI, but there are no studies on the effect of RIP3 inhibitors on LIRI.
[0008] GSK'872 is a specific RIP3 kinase inhibitor that inhibits RIP1-RIP3-MLKL pathway-mediated programmed cell necrosis by inhibiting RIP3 kinase activity. In a variety of disease models such as lupus nephritis, cerebral ischemia-reperfusion injury, and LPS-induced lung injury, GSK'872 was found to reduce damage by inhibiting programmed cell necrosis. However, the effect of GSK'872 on LIRI remains to be elucidated.
[0009] Therefore, this study used a rat orthotopic left lung transplantation model to detect the effect of GSK'872 on rat LIRI induced by lung transplantation. The results can clarify the role of RIP3 in mediating ischemia-reperfusion injury in lung transplantation, provide new ideas for PGD treatment after lung transplantation, and provide a more optimized treatment strategy for LIRI induced by various factors in clinical practice. Summary of the invention
[0010] The purpose of the present invention is to provide a use of a RIP3 inhibitor in preparing a pharmaceutical composition for alleviating ischemia-reperfusion injury in lung transplantation.
[0011] In order to achieve the above object, the present invention is implemented by the following technical solutions: In the present invention, GSK'872 can reduce programmed necrosis and cell pyroptosis of transplanted lung cells by inhibiting RIP3-dependent pulmonary macrophage inflammation, and reduce inflammation of peripheral blood neutrophils by inhibiting RIP3-dependent NLRP3 inflammasome pathway and NFκB pathway, thereby improving ischemia-reperfusion injury of rat lung transplantation.
[0012] In the present invention, GSK'872 is administered in three ways: cold ischemia stage / donor preservation solution administration, reperfusion stage / recipient intraperitoneal injection administration, and cold ischemia + reperfusion / full administration. It is found that GSK'872 administered in donor preservation solution and intraperitoneal injection of recipients have significant protective effects on lung transplantation. Among them, administration of GSK'872 in the cold ischemia stage can significantly inhibit RIP3 phosphorylation in transplanted lung tissue and inhibit the classical programmed cell necrosis pathway mediated by it, and also inhibit the expression and activation of related molecules NLRP3 and GSDMD in the RIP3-dependent NLRP3 inflammasome pathway.
[0013] The experimental results of the present invention show that the cells that undergo programmed necrosis in rat transplanted lungs are mainly type II alveolar epithelial cells and lung macrophages. In SD rats, type I alveolar epithelial cells, type II alveolar epithelial cells, and lung macrophages account for approximately 1 / 11, 1 / 7, and 1 / 33 of the total number of alveolar cells, respectively. Alveolar type II epithelial cells are not only numerous, but also very important as stem cells that can differentiate into alveolar type I epithelial cells. They have been considered as an important target for the treatment of acute lung injury. We found that after GSK'872 was administered during the cold ischemia stage of the lung (i.e., administered in lung preservation fluid), the programmed necrosis of type II alveolar epithelial cells and lung macrophages could be reduced; however, the results of our cold ischemia-reperfusion cell model excluded the direct protective effect of GSK'872 on alveolar epithelial cells, so it can be clearly stated that GSK'872 administered during the cold ischemia stage of the lung can reduce lung injury and inflammation by directly reducing the programmed necrosis of lung macrophages.
[0014] Macrophage programmed necrosis can cause cells to release a large number of inflammatory factors and damage-associated molecular patterns (DAMPs), thereby aggravating the damage to lung parenchymal cells. At the same time, inflammatory factors such as IL-1β released by activated surviving macrophages can recruit other inflammatory cells such as neutrophils to infiltrate the lungs. In addition, phosphorylated MLKL does not necessarily represent programmed necrosis. pMLKL also has non-programmed necrosis effects. After pMLKL is transferred to the cell membrane, it needs to overcome other negative regulatory mechanisms before it can cause cell programmed necrosis. This suggests that although GSK'872 inhibits the phosphorylation of MLKL in alveolar type II epithelial cells and lung macrophages, its effect in alleviating transplant lung inflammation can be achieved not only by inhibiting cell programmed necrosis, but also through other mechanisms.
[0015] The experimental results of the present invention also show that the administration of GSK'872 during the cold ischemia stage of the rat donor lung not only inhibits the programmed necrosis of cells in the transplanted lung, but also inhibits the RIP3-dependent NLRP3 inflammasome pathway. This indicates that the administration of GSK'872 during the cold ischemia stage can also reduce the acute injury and inflammation of the transplanted lung by inhibiting the RIP3-dependent NLRP3 inflammasome pathway in the donor lung macrophages.
[0016] The experimental results showed that GSK'872 inhibited the protein level of N-GSDMD in transplanted lungs only after it was given during the reperfusion phase, but did not affect the protein level of NLRP3, and inhibited the activation of the NFκB pathway in the lungs induced by transplantation. Although NFκB activation leads to increased levels of NLRP3, we speculate that in whole animals, GSK'872 inhibits the transcription of GSDMD by directly inhibiting the activation of NLRP3 or by inhibiting the activation of the NFκB pathway, thereby reducing the level of N-GSDMD and inhibiting cell pyroptosis in transplanted lungs.
[0017] The experimental results also found that the MPO level in the serum of recipient rats given GSK'872 during reperfusion was significantly decreased after lung transplantation, indicating that GSK'872 can reduce the inflammatory effect of neutrophils; GSK'872 can inhibit the formation of NETs and the increase in MPO secretion caused by LPS treatment of isolated and purified rat peripheral blood neutrophils, indicating that GSK'872 has a significant inhibitory effect on neutrophil inflammation. However, we found that although GSK'872 inhibited the phosphorylation of RIP3 in peripheral blood neutrophils, the expression of MLKL in rat peripheral blood neutrophils was low and there was almost no pMLKL, indicating that GSK'872 does not inhibit neutrophil inflammation by inhibiting the classic RIP3-MLKL cell programmed necrosis pathway.
[0018] The experimental results further found that after GSK'872 was administered to rat peripheral blood neutrophils, it could inhibit the LPS-induced activation of the neutrophil NFκB pathway and NLRP3 inflammasome pathway; moreover, after administration of GSK'872, not only the LPS-induced increase in N-GSDMD levels in rat peripheral blood neutrophils was inhibited, but also the baseline levels of NLRP3 and GSDMD were reduced.
[0019] Compared with the prior art, the present invention has the following beneficial effects: GSK'872 has an improving effect on rat lung transplant injury, and has different mechanisms of action when administered at different times: GSK'872 administered during the cold ischemia stage can inhibit inflammation mediated by pathways such as programmed necrosis mediated by RIP3 phosphorylation in lung macrophages, thereby reducing ischemia-reperfusion injury of transplanted lungs; GSK'872 administered during the reperfusion stage can inhibit RIP3 phosphorylation to inhibit the neutrophil NLRP3 inflammasome pathway and NFκB pathway to alleviate peripheral blood neutrophil inflammation in recipient rats, thereby indirectly protecting against lung transplant injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is a graph showing that GSK'872 reduces rat transplanted lung hemorrhage, edema, neutrophil infiltration and inflammatory factor secretion.
[0021] Figure 1 A in the figure shows the whole lung photograph of rats in each group 4 hours after left lung transplantation, HE staining of paraffin-embedded sections of the left lung (transplanted lung) of rats in each group 4 hours after transplantation, and MPO immunohistochemical staining of paraffin sections of transplanted lungs.
[0022] Figure 1 B is a statistical chart of the number of red blood cells in the alveoli of transplanted lungs of rats in each group.
[0023] Figure 1 C in the figure is a statistical graph showing the proportion of the edema zone around the transplanted lung vessels to the total vascular area in each group of rats.
[0024] Figure 1 D in the figure is a statistical diagram of the number of MPO-positive cells in the alveoli of transplanted lungs of rats in each group.
[0025] Figure 1 E in the figure is a statistical graph of IL-6 concentration in the serum of each group of rats after lung transplantation detected by ELISA.
[0026] Figure 1 F is the statistical graph of IL-1β concentration in serum of rats in each group after lung transplantation detected by ELISA.
[0027] Figure 1G in the figure is the statistical graph of TNF-α concentration in serum of rats in each group after lung transplantation detected by ELISA.
[0028] Figure 2 This figure shows that GSK'872 inhibits programmed necrosis in rat lung transplantation.
[0029] Figure 2 A in the figure is a typical WB image of programmed cell death-related proteins in rat lung tissue homogenate.
[0030] Figure 2 B is a statistical graph of RIP1 phosphorylation levels in lung tissues of rats in each group detected by WB.
[0031] Figure 2 C in the figure is a statistical graph of RIP3 phosphorylation levels in lung tissues of rats in each group detected by WB.
[0032] Figure 2 D in the figure is a statistical graph of MLKL phosphorylation levels in lung tissues of rats in each group detected by WB.
[0033] Figure 2 E in the figure is a typical WB image of Cleaved Caspase3 (CC3) in the lung tissues of rats in each group.
[0034] Figure 2 F in the figure is the statistical graph of CC3 levels in lung tissues of rats in each group detected by WB.
[0035] Figure 2 G in the figure is the statistical graph of HMGB1 concentration in serum of rats in each group after lung transplantation detected by ELISA.
[0036] Figure 2 H in the figure is the statistical graph of IL-6 concentration in lung tissue homogenate of each group of rats transplanted by ELISA.
[0037] Figure 3 This is the immunofluorescence co-staining display of programmed necrosis marker protein pMLKL and vascular endothelial cell and alveolar type I epithelial cell marker proteins in the paraffin sections of lung tissues of rats in each group.
[0038] Figure 4 This is the immunofluorescence co-staining display of programmed necrosis marker protein pMLKL and alveolar type II epithelial cell marker protein in the paraffin sections of lung tissues of rats in each group.
[0039] Figure 4 A in the figure is a display of immunofluorescence co-staining of pMLKL and SPC in paraffin sections of lung tissue of rats in each group.
[0040] Figure 4B is a statistical graph showing the ratio of pMLKL and SPC double-positive cells to total SPC-positive cells in the paraffin sections of the lung tissues of rats in each group.
[0041] Figure 5 This is the immunofluorescence co-staining display of programmed necrosis marker protein pMLKL and lung macrophage marker protein in the paraffin sections of lung tissue of rats in each group.
[0042] Figure 5 A in the figure shows the immunofluorescence co-staining of pMLKL and CD68 (macrophage marker) in paraffin sections of lung tissues of rats in each group after cold ischemia treatment (donor lungs) and cold ischemia-reperfusion treatment (transplanted lungs).
[0043] Figure 5 B is a statistical graph of the number of macrophages under high power field (HPF, 400×) on paraffin sections of lung tissue of rats in each group.
[0044] Figure 5 C in the figure is a statistical graph showing the ratio of the number of pMLKL fluorescence positive macrophages to the total number of macrophages in the paraffin sections of the lung tissues of rats in each group.
[0045] Figure 6 This is a diagram showing that GSK'872 inhibits the NLRP3 inflammasome pathway in rat lung transplants.
[0046] Figure 6 A in the figure is a schematic diagram of WB detection of the levels of NLRP3 and NFκB pathway-related proteins in the lung tissue homogenates of rats in each group.
[0047] Figure 6 B is a schematic diagram of WB detection of NLRP3 levels in lung tissues of rats in each group.
[0048] Figure 6 C in FIG. 1 is a schematic diagram of WB detection of IκBα phosphorylation levels in lung tissues of rats in each group.
[0049] Figure 6 D in the figure is a schematic diagram of ELISA detection of IL-1β content in transplanted lungs of rats in each group.
[0050] Figure 6 Figure E is a schematic diagram of ELISA detection of serum MPO levels in rats of each group after lung transplantation.
[0051] Figure 6 F in FIG. 1 is a schematic diagram of WB detection of N-GSDMD levels in lung tissues of rats in each group.
[0052] Figure 7 The figure shows the immunofluorescence co-staining of pRIP3 and neutrophil marker protein in the paraffin sections of lung tissues of rats in each group.
[0053] Figure 7 A in the figure shows the immunofluorescence co-staining of pRIP3 and MPO (neutrophil marker) in paraffin sections of lung tissues of rats in each group after cold ischemia treatment (donor lungs) and cold ischemia-reperfusion treatment (transplanted lungs).
[0054] Figure 7 B is a statistical graph showing the proportion of pRIP3 fluorescence and MPO fluorescence double-positive cells to total MPO-positive cells on the paraffin sections of the lung tissues of rats in each group.
[0055] Figure 8 This figure shows that GSK'872 inhibits peripheral blood neutrophil inflammation in rats after lung transplantation.
[0056] Figure 8 A in the figure is a diagram showing the NETs formation of peripheral blood neutrophils in rats of each group.
[0057] Figure 8 B in the figure is the scoring and statistical graph of the NETs formation level of peripheral blood neutrophils in each group of rats.
[0058] Figure 8 C in the figure is the concentration of MPO in the cell supernatant of peripheral blood neutrophils of each group of rats detected by ELISA and a statistical graph is drawn.
[0059] Figure 8 D in the figure is a typical WB image of peripheral blood neutrophils in each group of rats.
[0060] Figure 8 E in the figure is a statistical graph of pRIP3 levels in peripheral blood neutrophils of rats in each group detected by WB.
[0061] Figure 8 F in the figure is a statistical graph of NLRP3 levels in peripheral blood neutrophils of rats in each group detected by WB.
[0062] Figure 8 The G in the figure is the statistical graph of GSDMD level of peripheral blood neutrophils in each group of rats detected by WB.
[0063] Figure 8 H in the figure is the statistical graph of N-GSDMD level of peripheral blood neutrophils in each group of rats detected by WB.
[0064] Figure 8 I in the figure is the statistical graph of the pIκBα level of peripheral blood neutrophils in each group of rats detected by WB. DETAILED DESCRIPTION
[0065] The embodiments of the present invention are described in further detail below in conjunction with the accompanying drawings.
[0066] 1. Experimental Materials 1.1 Experimental animals One hundred and four healthy male specific pathogen–free (SPF) Sprague Dawley (SD) rats, 8–12 weeks old and weighing approximately 250–300 g, were purchased from the Animal Experiment Center of Hangzhou Medical College.
[0067] 1.2 Experimental drugs and reagents Table 1 name factory Product name or item number GSK'872 MedChemExpress HY-101872 1.3 Experimental Antibodies (for Western Blotting) Table 2 name factory Part Number Working concentration Rabbit Inhibitor of nuclear factor kappa Balpha (IκBα) antibody Shanghai Bio-Tech Biotechnology Co., Ltd. AF5204 1:1000 Rabbit phosphorylated MLKL (Phospho MLKL, pMLKL) antibody Abcam, UK ab196436 1:1000 Rabbit Gasdermin D (GSDMD) Antibody Abcam, UK ab209845 1:1000 Mouse Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody Proteintech 60004-1-Ig 1:10000 Mouse phosphorylated IκBα (Phospho IκBα, pIκBα) antibody Cell Signaling Technology (CST) 9246S 1:1000 Rabbit RIP3 Antibody CST Corporation 95702S 1:1000 Rabbit phosphorylated RIP3 (Phospho RIP3, pRIP3) antibody CST Corporation 91702S 1:1000 Rabbit Nucleotidebindingoligomerizationdomain likereceptor thermal protein domainassociatedprotein 3 (NLRP3) antibody CST Corporation 15101S 1:1000 Rabbit RIP1 Antibody CST Corporation 3493S 1:1000 Rabbit phosphorylated RIP1 (Phospho RIP1, pRIP1) antibody CST Corporation 53286S 1:1000 Rabbit Cleaved Caspase3 (CC3) Antibody CST Corporation 9661S 1:1000 Rabbit MLKL Antibody CST Corporation 37705S 1:1000 Horseradish peroxidase (HRP)-labeled goat anti-mouse IgG secondary antibody CST Corporation 7076S 1:10000 HRP-labeled goat anti-rabbit IgG secondary antibody Jackson Corporation 111-035-003 1:10000 1.4 Experimental antibodies (for immunofluorescence or immunohistochemistry staining) Table 3 name factory Part Number Working concentration Rabbit pMLKL Antibody Abcam, UK ab196436 1:100 Rabbit Aquaporin 5 (AQP5) Antibody Abcam, UK ab78486 1:300 Rabbit plateletendothelial cell adhesion molecule-1 (PECAM-1 / CD31) antibody Abcam, UK ab182981 1:1000 Rabbit Myeloperoxidase (MPO) Antibody Abcam, UK ab208670 1:3000 Rabbit Surfactant-associated protein C (SPC) antibody Thermo Fisher Scientific Inc. PA5-71680 1:200 Rabbit CD68 Antibody CST Corporation 97778S 1:400 Rabbit pRIP3 Antibody CST Corporation 91702S 1:50 1.5 Experimental kit Table 4 name factory Part Number Rat MPO ELISA Kit Wuhan Fine Biotechnology Co., Ltd. ER0142 Rat High mobility group protein B1 (HMGB1) ELISA kit Wuhan Fine Biotechnology Co., Ltd. ER0291 Rat HMGB1 ELISA Kit Elabscience, USA E-EL-R0505c Rat Interleukin-6 (IL-6) ELISA Kit Boster Biotechnology Co., Ltd. EK0412 Rat tumor necrosis factor-α (TNF-α) ELISA kit Boster Biotechnology Co., Ltd. EK0526 Rat Interleukin-β (IL-β) ELISA Kit Boster Biotechnology Co., Ltd. EK0393 Rat peripheral blood neutrophil separation kit Beijing Solable Technology Co., Ltd. P9203 1.6 Reagent Configuration 1.6.1 GSK'872 stock solution (5 mg / mL) Table 5 GSK'872 5 mg DMSO 1 mL 1.6.2 Heparinized low-potassium dextran (LPD) solution Table 6 Element content Glucan 40,000 50 g NaCl 7.948 g KCl 0.447 g <![CDATA[MgSO4]]> 0.096 g <![CDATA[Na2HPO4·12H2O]]> 0.287 g glucose 0.900 g Mannitol 3.640 g <![CDATA[NaHCO3]]> 0.084 g <![CDATA[CaCl2]]> 0.033 g Preparation method: 50g of dextran 40,000 is dissolved in 500 mL 80 °C ddH2O, then other components are added, pH is adjusted to 7.2-7.4 with dilute hydrochloric acid or dilute sodium hydroxide, the volume is fixed to 1 L, filtered with a 0.22 μM microporous filter membrane, and then divided into 50 mL centrifuge tubes, sealed with sealing film and stored at 4 °C for use. When using, 1mL of 1000 IU / mL heparin sodium solution should be added to prepare 4°C heparinized LPD solution.
[0068] 1.6.3 Heparinized LPD solution containing GSK'872 Table 7 GSK'872 stock solution 20 μL Heparinized LPD solution 50 mL 1.6.4 GSK'872 working solution (0.125 mg / mL, for intraperitoneal injection in rats) Table 8 GSK'872 stock solution 37.5 μL Add from top to bottom, mix until clear before adding the next component. PEG300 600 μL Add from top to bottom, mix until clear before adding the next component. Tween-80 75 μL Add from top to bottom, mix until clear before adding the next component. Normal saline 787.5 μL Add from top to bottom, mix until clear before adding the next component. 1.6.5 LPS solution Table 9 LPS 4 mg ddH2O 2 mL 2. Experimental Methods 2.1 Orthotopic transplantation model of left lung in rats 2.1.1 Induction of anesthesia: Rats were randomly assigned and deprived of water and food for 8 hours. The lighter rats were selected as donors and the heavier rats were selected as recipients. After weighing the donors, atropine sulfate (dose: 0.2 mg / kg) was injected intramuscularly to reduce respiratory secretions. Ten minutes later, 1% sodium pentobarbital (dose: 0.03 g / kg) was injected intraperitoneally to induce anesthesia. After 3-5 minutes, the rats lost consciousness, their muscles relaxed, and their legs did not retract, which was considered to be a successful induction of anesthesia. 2.1.2 Oral intubation under direct vision, isoflurane inhalation anesthesia: Use an electric shaving machine to shave the hair on the front neck of the rat, use a light source to illuminate the neck, and use ophthalmic curved forceps to go deep into the mouth and lift the root of the tongue. The glottis can be seen opening and closing, which is consistent with the respiratory rate. A 16G venous indwelling needle with a needle core is inserted into the trachea, the inner core is pulled out, and the ventilator is connected. The ventilator parameters are set as follows: tidal volume 10ml / kg, frequency 90 times / min, positive end-expiratory pressure 3 cmH2O, and a sterile dressing is used to fix the tracheal intubation. The parameters of the gas anesthesia machine are set as follows: flow rate 0.5-0.7 L / min, isoflurane concentration 2%; 2.1.3 Heparinized donors: Rats were fixed in a supine position on a homemade fixation board and anesthetized by endotracheal intubation. The rats’ abdominal and chest hair was shaved and disinfected with 75% alcohol. The abdomen was opened with coarse scissors in a cross-shaped incision. The peritoneal vein was exposed with a cotton swab. Heparin sodium solution (dose: 500 IU / kg) was injected into the peritoneal vein with a 1 ml syringe. After the injection, the puncture point was pressed with a cotton ball for 5 min. 2.1.4 LPD solution perfusion, removal and preservation of donor lungs: 5 minutes after heparin injection, the rats were killed by cutting the abdominal artery and vein, the abdominal wall was cut along the lower edge of the costal arch of the rats, and the chest wall and left and right clavicles of the rats were cut upward in an arc along the left and right midaxillary lines until the incisions on both sides merged under the mandible, and the anterior chest wall of the rats was removed. The thymus tissue covering the heart was separated and removed with forceps to expose the aorta and pulmonary artery, and the left and right atrial appendages were cut with elbow tissue scissors. The left lung was perfused from the pulmonary artery with heparin-containing LPD solution (heparin sodium concentration: 20 IU / kg), and the lungs turned from pink to white, indicating that the perfusion was successful. The heart and lung tissues were removed and the trachea and esophagus were ligated with 3-0 non-absorbable surgical sutures (silk thread), and the ligated heart and lung tissues were immersed in 4 ℃ LPD solution; 2.1.5 Separate the donor's left lung and cannulate it: Separate the left lung from the heart and lung tissue, and separate the left main bronchus, left pulmonary artery, and left pulmonary vein of the left lung, leaving as long a length as possible. Use 18G, 16G, and 14G indwelling needle cannulas to cannulate the left pulmonary artery, left pulmonary vein, and left main bronchus in turn, with a cannula length of about 1.5-2 mm. Tie the cannula tightly with 8-0 silk thread. After the cannula is completed, use a 24G intravenous indwelling needle core with the needle tip removed to explore the left pulmonary artery and left pulmonary vein to determine the patency of the blood vessels after the cannula to prevent adhesion of the inner wall of the blood vessels and torsion of the blood vessels. Place the left lung on a 4 ℃ ice plate covered with multiple layers of gauze soaked in LPD liquid, cover with gauze soaked in LPD liquid to keep it moist, and wait for subsequent transplantation; 2.1.6 Recipient preparation - thoracotomy, left hilar separation: The steps of anesthesia and tracheal intubation of recipient rats are the same as before. The anesthetized and intubated rats are removed from the fixation board and placed in the right side lying position on the surgical pad. Use electric clippers to shave the hair of the rat's chest wall (up to the shoulder, down to the left hypochondrium, front to the anterior midline, and back to the posterior midline). Disinfect the prepared skin area with povidone iodine solution 3 times. Open the chest along the ribs from the 3rd and 4th intercostal spaces, from the front to the strongest point of the heart beat, and back to 2 cm from the posterior midline. The total length of the skin incision is 3-4 cm. The muscles and other tissues underneath were cut layer by layer with an electrocoagulation hemostat until the ribs and intercostal muscles were seen, and the muscles and other tissues attached to them were peeled off to expose the approximate shape of the 3rd and 4th intercostal spaces and the 2 ribs above and below them. The chest wall was cut horizontally with elbow tissue scissors at the upper edge of the ribs below the 3rd and 4th intercostal spaces, and the bleeding was stopped with an electrocoagulation hemostat to expose the lung tissue underneath. One end of the incision was 2 cm away from the anterior midline. An incision of about 2-3 cm was made, and an eyelid retractor was inserted and retracted. At the same time, the rat was placed in a supine position tilted 45° to the right so that the left chest was higher than the right chest. A cotton swab was used to slightly open the dorsal side of the left lung, and the wide azygos vein close to the dorsal side of the inner chest wall could be seen. The chest wall incision was extended dorsally to 0.5 mm away from the azygos vein. Use a cotton swab to pull the left lung out of the chest cavity to expose the hilum, and use a curved full-tooth hemostatic forceps to fix the left lung lobe. While exposing the thickest and longest branch of the left pulmonary vein clearly, the clamping part should be as far away from the hilum as possible to reduce the tension of the vascular clamp pulling the hilum. Finally, use the DIEFFENBACH vascular clamp to clamp the ear handle of the vascular clamp near the table to form a stable structure that can support the vascular clamp. Use micro curved forceps to carefully separate the left main bronchus, left pulmonary artery, and left pulmonary vein. Move gently to prevent heavy bleeding. Use 3-0 non-absorbable surgical sutures (silk thread) to close the left pulmonary vein with a single ligature. The ligature should not be too tight, just tighten the knot. Use a micro vascular clamp or a micro-closer to clamp the left pulmonary artery. After clamping the artery, use sutures to fix the micro-closer to the eyelid retractor to prevent it from moving at will to cover the field of vision or hinder the anastomosis of the left pulmonary vein and the left main bronchus; 2.1.7 Anastomosis of the left pulmonary artery and vein and the left main bronchus: From the tail end to the head end, the left pulmonary vein, the left main bronchus, and the left pulmonary artery are anastomosed in sequence. At the intersection of the main branches of the left pulmonary vein, an untied surgical knot is reserved with 8-0 non-absorbable surgical suture (nylon thread). The reserved surgical knot loop diameter is about 5 mm. The two ends of the knot need to be long enough, about 4 cm each, extending outside the left chest incision. 0.01 ml of 1000 U / ml heparin sodium solution is injected on the thickest branch of the left pulmonary vein at the lower edge of the left lung, about 3 mm away from the distal end of the intersection of the two main branches of the left pulmonary vein. Then, at the puncture point, a 2 mm long incision is made perpendicular to the long axis of the trachea with microscopic straight scissors. Do not cut too deep to completely cut off the left pulmonary vein branch. Only 1 / 4-1 / 3 of the circumference of the left pulmonary vein branch needs to be cut off. Stop bleeding appropriately. Use micro-curved forceps to hold the micro-closed device and translate the donor's left lung to the top of the recipient's left lung. Remove the micro-closed device clamped on the left main bronchus of the donor lung. Use the micro-curved forceps in the right hand to gently lift the vascular wall above the proximal end of the left pulmonary vein incision to expose the incision. Use another pair of micro-curved forceps in the left hand to firmly grasp the cannula wall of the donor's left pulmonary vein and insert it into the recipient's left pulmonary vein incision in a direction parallel to the recipient's left pulmonary vein trunk until the cannula completely enters the left pulmonary vein trunk. The assistant helps to use a surgical knot to firmly tie the recipient's left pulmonary vein wall to the donor's left pulmonary vein cannula, continue to tighten the knot, and then use another suture to tie one or more knots at the cannula to improve the reliability of the anastomosis. The second anastomosis is to the left main bronchus. The above method is also used to reserve a surgical knot. An incision is made in the left main bronchus as distally as possible. The incision should occupy 1 / 3-1 / 2 of the circumference of the left main bronchus. The cannula is inserted into the incision as quickly as possible and the knot is tied tightly to prevent insufficient ventilation of the recipient's right lung due to tracheal rupture and air leakage. After the first surgical knot is tied, one or more surgical knots need to be tied at different positions of the cannula to improve reliability, just like the left pulmonary vein anastomosis.The last part of the anastomosis is the left pulmonary artery. The part of the left main bronchial stump covering the left pulmonary artery at the root of the left lung is cut open to expose the left pulmonary artery as long as possible. After reserving the thread knot in the same way, use micro curved forceps to gently clamp the upper part of the left pulmonary artery, and use micro straight scissors to cut an incision perpendicular to the long axis of the left pulmonary artery on the upper wall of the left pulmonary artery. The incision occupies 1 / 3-1 / 2 of the circumference of the left pulmonary artery. Drop a drop of 1000 U / ml sodium heparin solution on the incision. The surgeon gently pulls the recipient's left pulmonary artery incision close to the surgeon with a pair of micro curved forceps in his right hand, and the assistant uses a pair of micro straight forceps (tip width 0.3 mm) Lift the arterial wall at the proximal end of the incision from above to form a hole for convenient insertion of the cannula. Hold another pair of micro curved forceps in the left hand to clamp the cannula wall of the donor's left pulmonary artery and insert it into the recipient's left pulmonary artery incision in a direction parallel to the recipient's left pulmonary artery until the cannula completely enters the left pulmonary artery. The assistant releases the clamped upper wall of the left pulmonary artery and holds the micro needle holder instead to cooperate with the operator to tie the recipient's left pulmonary artery wall to the donor's left pulmonary artery cannula with the reserved knot. Then tie a second or more knots at different positions of the cannula to improve reliability. 2.1.8 Opening and reperfusion of the left lung: First, open the left pulmonary vein, cut one end of the knot that occludes the recipient's left pulmonary vein close to the knot, carefully pull the other end of the knot that has not been cut with micro-curved forceps, and use another pair of micro-curved forceps to gently pull the knot to untie the knot. After opening the left pulmonary vein and before opening the left pulmonary artery, the donor's left lung needs to be fully ventilated to allow the alveoli to fully expand and prevent postoperative atelectasis. Then open the micro-closer at the left pulmonary artery, and you can see that the donor's left pulmonary artery fills up rapidly and the donor's left lung turns red rapidly. When the donor's left lung turns completely red, use scissors to cut off the recipient's left lung fixed with a vascular clamp close to the anastomosis and trim the anastomosis of the left pulmonary artery and vein and the left main bronchus so that the stump and surrounding tissues do not affect the patency of the three tubes; 2.1.9 Suturing the chest wall and resuscitation after anesthesia: Gently return the transplanted left lung to the chest cavity, place the rat in the right lateral position, and use a 3-0 suture needle with a surgical knot to close the innermost layer of the chest wall. Then suture the muscle layer and skin in sequence. After suturing, disinfect the incision again with iodine, and place the rat in a prone position. During suturing, gradually adjust the dose of gas anesthesia until the concentration of gas anesthetic is 0. Wait for about 30 minutes to 1 hour, and the rat will gradually breathe spontaneously. When the spontaneous breathing is strong, remove the endotracheal tube. After about 1 hour after the breathing returns to a stable state, the rat will be fully awake. Transfer the transplanted rat to a breeding box and place it in a warm environment until the time is right to remove the mold.
[0069] 2.2 Grouping of rat left lung orthotopic transplantation experiment A total of 104 Sprague Dawley (SD) rats were randomly divided into 5 groups: a sham operation group (Sham group, n=8; n represents the number of rats used in the experiment, the same below), which did not receive any treatment except left thoracotomy and mechanical ventilation for 180 min after thoracotomy after endotracheal intubation and ventilator-assisted ventilation; the remaining 96 rats were randomly divided into donor and recipient rats, and 48 rats underwent orthotopic left lung transplantation with a cold ischemia time of 18 h. After 4 h of reperfusion, the transplanted left lungs of the rats and the serum of the recipients were obtained for subsequent detection. 48 rats in the lung transplantation model group were divided into 4 groups: vehicle control group (Vehicle group, n=12), group given GSK'872 throughout the whole process (Donor+Recipient group, D+R group, n=12), group given GSK'872 only during the cold ischemia stage (Donor group, D group, n=12), and group given GSK'872 only during the reperfusion stage (Recipient group, R group, n=12).
[0070] In the cold ischemia phase, the drug-administered groups (group D and group D+R) needed to add 5 μM GSK'872 to the lung perfusion and preservation solution (LPD solution); in the reperfusion phase, the drug-administered groups (group R and group D+R) needed to be intraperitoneally injected with GSK'872 (0.75 mg / kg) 1 h before reperfusion of the recipient rats; in the Vehicle, D, and R groups, the corresponding solvents (20 μL DMSO added to the LPD solution or 6 mL / kg of the solvent injected intraperitoneally into the recipient rats) were all administered in the phases (cold ischemia phase and / or reperfusion phase) when GSK'872 was not administered.
[0071] 2.3 Routine histological analysis Five high-power fields (400×) were randomly selected from the left lung sections of each sample. The degree of lung injury was quantitatively evaluated by calculating the proportion of pulmonary vascular edema bands under HE staining, counting the number of red blood cells under HE staining, and the number of neutrophils under MPO immunohistochemical staining. The average value of the five HPFs was taken to represent the corresponding detection index level of the sample. The proportion of pulmonary vascular edema bands was calculated by the proportion of pulmonary vascular edema bands to the total area of blood vessels including pulmonary vascular edema bands.
[0072] 2.4 Construction of in vitro activation model of rat peripheral blood neutrophils 2.4.1 Preheat PBS, complete culture medium, Solution A and Solution C in the rat peripheral blood neutrophil extraction kit, and red blood cell lysis solution, and sterilize them under ultraviolet light in a biosafety cabinet for 30 min; 2.4.2 Four SD rats weighing about 250 g were injected with 1000 IU sodium heparin into the peritoneal vein. 5 min later, blood (approximately 30 mL) was drawn from the peritoneal vein. 2.4.3 Prepare 6 7 mL centrifuge tubes, moisten the tubes with 100 μL EDTA solution, add 5 mL of blood to each tube, and invert to mix slightly to prevent clotting; 2.4.4 In the biosafety cabinet, take 8 glass test tubes and slowly add 4 mL of solution A and 2 mL of solution C to each tube, so that a clear layer is formed between solution A and solution C; 2.4.5 Slowly add about 4 mL of rat peripheral blood into the above 8 glass test tubes respectively, so that the blood and solution C form distinct layers. Finally, each glass test tube contains blood, solution C, and solution A from top to bottom, with a total volume of 10 mL. 2.4.6 Centrifuge at 1200 g for 25 min at room temperature. After centrifugation, the red blood cells in the upper layer have settled to the bottom layer, and a thin milky white neutrophil layer can be seen between the A and C liquid layers; 2.4.7 Pipette all the neutrophil layer and liquid A layer from the 8 glass test tubes into another 4 15 mL centrifuge tubes, add PBS to each tube up to 15 mL, gently invert upside down to mix, and centrifuge at 500 g for 10 min at room temperature; 2.4.8 Discard the supernatant, add 2 mL of red blood cell lysis buffer to each tube, gently pipette to mix, and collect into a 15 mL centrifuge tube. Lyse red blood cells on ice for 5 min, and centrifuge at 500 g for 10 min at room temperature; 2.4.9 Discard the supernatant, resuspend the cells in 4 mL of PBS, take 10 μL of it and dilute it in 190 μL of PBS and mix well, then take 20 μL of it and drop it on a cell counting plate to count the cells; 2.4.10 Take 3 million neutrophils, centrifuge at 500 g for 10 min at room temperature, discard the supernatant, add 1 mL of complete medium (add 4 μL of 5 mg / mL GSK'872 solution or 4 μL of DMSO), and pretreat at 37 °C for 1 h; 2.4.11 Add 10 μL of 2 mg / mL LPS solution (add 10 μL ddH2O to the control group), pipette to mix, and incubate at 37°C for 2 h; 2.4.12 Centrifuge at 300 g for 10 min at room temperature and freeze the supernatant at -80 °C; 2.4.13 Add 40 μL PBS to the precipitate and mix well. Take 5 μL and drop it on a high-adhesion glass slide coated with poly-lysine. Then drop 5 μL of anti-fluorescence quenching sealing solution (containing DAPI) on the drop. Cover the cover glass and place it in a dark box. Observe the formation of neutrophil extracellular traps (NETs) under a microscope within 15 minutes. 2.4.14 The remaining 35 μL was centrifuged again at 2000 g for 10 min at room temperature, the supernatant was discarded, and the pellet was frozen and stored at -80 °C.
[0073] 2.5 Grouping of rat peripheral blood neutrophil activation experiment in vitro After extracting peripheral blood neutrophils from 4 rats and mixing them, they were divided into 4 groups, each containing 3 million neutrophils, namely Control group, Control+GSK'872 group, LPS group, LPS+GSK'872 group, and repeated 6 groups of experiments. Among them, the concentration of LPS in the culture medium was 20 μg / mL, the concentration of GSK'872 was 50 μM, and the Control group was only given the same volume of solvent.
[0074] 2.6 Scoring of extracellular trap formation of rat peripheral blood neutrophils Five HPFs (400×) were randomly selected from the cell smear of each sample, and each HPF was scored according to the following scoring criteria. The average NETs score of the five HPFs was used as the NETs score of the sample: Table 10 0 points All cell nuclei in the field of view are intact 1 point Less than 10% of the nuclei in the field of view are fragmented and have no DAPI-positive filaments 2 points Less than 10% of the nuclei in the field of view are fragmented and have DAPI-positive filaments, but the total number of neutrophils connected by DAPI-positive filaments is less than 10%. 3 points 10%-50% of the cells in the field of view have fragmented nuclei, or neutrophils with DAPI-positive filaments in series account for 10%-50% of the total number of neutrophils 4 points 50%-90% of the cells in the field of view have fragmented nuclei, or neutrophils with DAPI-positive filaments in series account for 50%-90% of the total number of neutrophils 5 points More than 90% of the cell nuclei in the field of view are fragmented, or the neutrophils with DAPI-positive filaments in series account for more than 90% of the total number of neutrophils 2.7 Statistical analysis The data are expressed as mean ± standard deviation (SD) and analyzed using GraphPad Prism4.0. After excluding outliers using the ROUT test (Q = 1%), the D'agostino-Pearson test and Brown-Forsythe test were used to test the normality and homogeneity of variance of the data, respectively. For data with normal distribution and homogeneity of variance, one-way analysis of variance (one-way ANOVA) or two-way analysis of variance (two-way ANOVA) were used to compare statistical differences. For data that did not conform to the normal distribution or homogeneity of variance, the non-parametric test (Kruskal-Wakkis test) was used to compare statistical differences. A P value less than 0.05 was considered to be statistically significant.
[0075] 3. Experimental Results 3.1 GSK'872 reduces lung ischemia-reperfusion injury induced by lung transplantation in rats Reference Figure 1 A~G in it. Among them, Figure 1A in the figure shows, from top to bottom, the whole lung photos of rats in each group 4 hours after left lung transplantation, HE staining of paraffin-embedded sections of the left lung (transplanted lung) of rats in each group 4 hours after transplantation, and MPO immunohistochemical staining of paraffin sections of transplanted lungs; Figure 1 B in the figure is a statistical diagram of the number of red blood cells in the alveoli of transplanted lungs of rats in each group; Figure 1 C in the figure is the statistical graph of the proportion of edema zone around transplanted lung blood vessels to the total blood vessel area in each group of rats; Figure 1 D in the figure is a statistical diagram of the number of MPO-positive cells in the alveoli of transplanted lungs of rats in each group; Figure 1 E in the figure is the statistical graph of IL-6 concentration in serum of rats in each group after lung transplantation detected by ELISA; Figure 1 F in the figure is the statistical graph of IL-1β concentration in serum of rats in each group after lung transplantation detected by ELISA; Figure 1 G in the figure is the statistical graph of TNF-α concentration in serum of rats after lung transplantation detected by ELISA. Among them, Sham: sham operation group; Vehicle: lung transplantation model group without GSK'872; Donor+Recipient / D+R: lung transplantation model group with GSK'872 given throughout the whole process; Donor / D: lung transplantation model group with GSK'872 given only in the cold ischemia stage; Recipient / R: lung transplantation model group with GSK'872 given only in the reperfusion stage.
[0076] This study first evaluated the improvement of GSK'872 on rat lung transplant injury at the pathological level ( Figure 1 A in the figure): At the macroscopic level, the left lungs of rats in each group of lung transplant modeling were significantly more red and swollen than those in the sham operation group (Sham group), indicating that there was some bleeding in the transplanted lungs after lung transplant modeling; and in the lung transplant modeling groups given GSK'872, whether the donors and recipients were both given drugs (D+R group), the donors were given drugs (drugs during the cold ischemia phase / donor lung perfusion fluid and lung preservation fluid were given, D group), and the recipients were given drugs by intraperitoneal injection (drugs during the reperfusion phase, R group), the pulmonary hemorrhage was improved compared with the lung transplant modeling group not given drugs (Vehicle group); paraffin-embedded sections of the transplanted lungs of each group were taken for HE staining, and microscopic observation showed that the number of red blood cells and the degree of vascular edema in the alveoli of each lung transplant modeling group were significantly increased compared with the sham operation group, and the number of red blood cells in the alveoli of each lung transplant modeling group given GSK'872 was reduced compared with the lung transplant modeling group not given drugs ( Figure 1 B in the figure), the degree of pulmonary vascular edema is reduced ( Figure 1 The damage in the transplanted lungs was alleviated, but it could not be restored to the level of the sham operation group. This shows that the above regimens of GSK'872 can reduce alveolar hemorrhage and vascular edema in the transplanted lungs.
[0077] After paraffin-embedded sections of the transplanted lung tissues of each group were obtained, MPO immunohistochemical staining was performed. It was found that the number of MPO-positive cells (neutrophils) in each lung transplant model group was significantly higher than that in the sham operation group, while the number of MPO-positive cells in the lung transplant model group (R group) that was given GSK'872 only during the reperfusion phase was reduced compared with the lung transplant model group that was not given the drug, but it did not decrease to the level of the sham operation group; the group that was given GSK'872 throughout the lung transplantation (D+R group) and the group that was given GSK'872 during the cold ischemia phase (D group) did not show a decrease in MPO-positive cells compared with the lung transplant model group that was not given the drug ( Figure 1 This suggests that administration of GSK'872 during the reperfusion phase can reduce neutrophil infiltration in the transplanted lung.
[0078] Secondly, this study measured the inflammatory biochemical indicators in the serum of recipient rats after lung transplantation. The results showed that the serum IL-6 ( Figure 1 E) and IL-1β ( Figure 1 The levels of IL-6 and IL-1β in the serum of rats after lung transplantation were significantly higher than those in the sham operation group. The administration of GSK'872 during the whole process (D+R group), the administration of GSK'872 only during the cold ischemia phase (D group), and the administration of GSK'872 only during the reperfusion phase (R group) all reduced the levels of IL-6 and IL-1β in the serum of rats after lung transplantation and made them insignificantly different from those in the sham operation group. This indicates that GSK'872 has the effect of alleviating acute inflammation in transplanted lung tissue. However, compared with the sham operation group, the serum TNF-α of the recipient rats in each lung transplantation group showed an upward trend, but only the lung transplantation modeling group (R group) that was only given GSK'872 during the reperfusion phase had a statistical difference from it, and the serum TNF-α concentration of each group of lung transplantation given GSK'872 was not significantly different from that of the lung transplantation group without drug administration ( Figure 1 in G).
[0079] 3.2 GSK'872 inhibits programmed necrosis of rat lung transplant cells 3.2.1 Western blot analysis of the left lung of the sham operation group and the transplanted lung tissues of each group to detect the levels of related proteins From the experimental results 3.1, it can be seen that GSK'872 has an improving effect on acute lung transplantation injury in rats of each medication group. As for the mechanism of GSK'872 improving acute lung transplantation injury in rats, this study first speculated that GSK'872, as a classic RIP3 phosphorylation inhibitor, inhibits programmed cell necrosis by inhibiting the phosphorylation of RIP3, thereby reducing transplanted lung injury. To confirm this speculation, the following experiments were conducted.
[0080] Reference Figure 2 A~H in. Figure 2 A is a typical WB image of programmed necrosis-related proteins in rat lung tissue homogenate; Figure 2 B in the figure is the statistical graph of RIP1 phosphorylation level in lung tissue detected by WB; Figure 2 C in the figure is the statistical graph of RIP3 phosphorylation level in lung tissue detected by WB; Figure 2 D in the figure is the statistical diagram of MLKL phosphorylation level in lung tissue detected by WB; Figure 2 E in the figure is a typical WB image of Cleaved Caspase3 (CC3) in lung tissue; Figure 2 F in the figure is the statistical graph of CC3 levels in lung tissue detected by WB; Figure 2 G in the figure is the statistical graph of HMGB1 concentration in serum of rats in each group after lung transplantation detected by ELISA; Figure 2 H in the figure is the statistical graph of IL-6 concentration in the homogenate of transplanted lung tissue of each group of rats detected by ELISA.
[0081] The levels of related proteins were detected by WB in the left lung of the sham operation group and the transplanted lung tissues of each group. Figure 2 A) shows that the phosphorylation level of RIP1 in each lung transplant model group was significantly higher than that in the sham operation group, but there was no significant difference in the phosphorylation level of RIP1 in each lung transplant model group given GSK'872 compared with the lung transplant model group not given the drug ( Figure 2 B). RIP3 phosphorylation levels in all lung transplantation modeling groups were significantly higher than those in the sham operation group. Only in the cold ischemia stage, the RIP3 phosphorylation in the transplanted lungs of rats in the group that received GSK'872 (group D) was significantly lower than that in the transplanted lungs of rats in the group that did not receive GSK'872, and was reduced to the level of the sham operation group ( Figure 2 C), indicating that among various administration methods, only GSK'872 administered during the cold ischemic phase inhibited the phosphorylation of RIP3 in transplanted lungs.
[0082] WB results also showed that the phosphorylation level of MLKL, a downstream protein of programmed necrosis, was significantly increased in all lung transplant modeling groups compared with the sham operation group. The MLKL phosphorylation level in the group that received GSK'872 only during the cold ischemia phase (group D) or only during the reperfusion phase (group R) was significantly lower than that in the transplanted lungs of the non-administered group, and was reduced to the level of the sham operation group. However, the MLKL phosphorylation level in the transplanted lungs that received GSK'872 throughout the entire process (group D+R) was not significantly different from that in the transplanted lungs of the non-administered group ( Figure 2 D in.
[0083] It can be seen that GSK'872 administered only during the cold ischemia phase inhibited programmed necrosis in the transplanted lungs by inhibiting RIP3 phosphorylation and reducing the phosphorylation level of MLKL. However, GSK'872 administered only during the reperfusion phase, although it also reduced the phosphorylation level of MLKL in the transplanted lungs, failed to significantly reduce the phosphorylation level of RIP3 in the transplanted lungs, suggesting that there are other factors that affect the phosphorylation of MLKL in the transplanted lungs.
[0084] There was no significant difference in the levels of pRIP3, pMLKL, and HMGB1 in the transplanted lungs of rats that were given GSK'872 throughout the entire course compared with the non-administered group. Combining the results of the later GSK'872 cytotoxicity experiment, we speculated that this may be due to the concentration-dependent toxicity of GSK'872 masking its protective effect.
[0085] ELISA was used to detect the HMGB1 concentration in the serum of the recipient rats in the sham operation group and each lung transplantation group and the IL-6 concentration in the transplanted lung tissue. The results showed that the HMGB1 concentration in the serum of the recipient rats in the lung transplantation group without medication (Vehicle group) was significantly higher than that in the sham operation group. Only after GSK'872 was given (D group) during the cold ischemia stage, the HMGB1 concentration in the serum of the recipient rats was significantly lower than that in the lung transplantation group without medication (Vehicle group) and was reduced to the level of the sham operation group; while the HMGB1 concentration in the serum of the lung transplantation recipient rats in the other two groups that were given medication was significantly higher than that in the sham operation group, but compared with the lung transplantation group without medication (Vehicle group), there was a downward trend but no statistical difference ( Figure 2 G in the figure). This suggests that the administration of GSK'872 only during the cold ischemia phase / in the preservation solution can significantly reduce cell necrosis in the transplanted lungs. In addition, the IL-6 levels in the lung tissues of the recipient rats in each lung transplantation group were significantly higher than those in the sham operation group. The administration of GSK'872 throughout the entire process (D+R group) or by the donor (D group) reduced the IL-6 levels in the lung tissues of the rats after lung transplantation and had no statistical difference from the sham operation group; however, the IL-6 concentration in the lung tissues of the rats after lung transplantation that were only administrated by the recipient (R group) was higher than that in the sham operation group but lower than that in the lung transplantation modeling group that was not administrated (Vehicle group) ( Figure 2 This suggests that GSK'872 reduces inflammation in transplanted lungs and is more effective when administered during the cold ischemia phase of the lung.
[0086] WB results also showed that the level of Cleaved-Caspase3 (CC3), a marker of apoptosis, in the left lung of the lung transplant group was significantly lower than that in the sham surgery group. The CC3 level in the GSK'872-treated groups showed an upward trend, but no statistical difference was observed ( Figure 2 The E in Figure 2 F), which suggests that in rat lung transplantation, the total cell apoptosis level of transplanted lungs is decreased, while GSK'872 has no improvement on the decrease of total cell apoptosis in transplanted lungs.
[0087] 3.2.2 Immunofluorescence co-staining of cell marker proteins in paraffin sections of the left lung of rats in each group Reference Figure 3There was no obvious programmed cell necrosis in the vascular endothelial cells and alveolar type I epithelial cells in the transplanted lungs of rats. After orthotopic transplantation of the left lung of rats, paraffin sections of the transplanted lungs were sliced and subjected to fluorescent staining of CD31, a marker of vascular endothelial cells, and immunofluorescent staining of AQP5, a marker of alveolar type I epithelial cells.
[0088] The paraffin sections of the left lungs of rats in each group were immunofluorescently co-stained with pMLKL (a marker of programmed necrosis) and SPC (a marker of alveolar type II epithelial cells), AQP5 (a marker of alveolar type I epithelial cells), CD31 (a marker of vascular endothelial cells), and CD68 (a marker of macrophages). The results showed that the number of positive cells for the programmed necrosis marker protein-phosphorylated MLKL (pMLKL) in the left lungs that underwent lung transplantation injury was significantly increased compared with the sham operation group, and there was no significant co-localization of pMLKL with the marker protein AQP5 of alveolar type I epithelial cells and the marker protein CD31 of vascular endothelial cells ( Figure 3 ), while SPC ( Figure 4 ) and macrophage marker protein CD68 ( Figure 5 ) The CCP localization was obvious, which suggested that programmed necrosis occurred in alveolar type II epithelial cells and macrophages in lung transplantation injury.
[0089] 3.2.3 SPC fluorescence detection of alveolar type II epithelial cells in rat transplanted lungs Reference Figure 4 A~B in. Figure 4 A in the figure shows immunofluorescence co-staining of pMLKL (programmed necrosis marker, green) and SPC (alveolar type II epithelial cell marker, red) in paraffin sections of rat lung tissue; Figure 4 B is a statistical graph showing the ratio of pMLKL and SPC double-positive cells to the total SPC-positive cells. Programmed necrosis of alveolar type II epithelial cells (SPC fluorescence positive) in rat transplanted lungs.
[0090] In addition, it can be seen that the proportion of pMLKL-positive alveolar type II epithelial cells in the transplanted lungs of rats that were given GSK'872 throughout the entire process (D+R group) and only given GSK'872 during the cold ischemia stage (D group) was significantly reduced compared with the model group without medication (Vehicle group), but did not drop to the level of the sham operation group; while the proportion of pMLKL-positive alveolar type II epithelial cells in the transplanted lungs of rats that were given medication only during the reperfusion stage (R group) was not significantly different from that of the model group without medication ( Figure 4 A, B in the figure indicate that adding GSK'872 to the organ preservation solution can significantly reduce the programmed necrosis of alveolar type II epithelial cells caused by lung transplantation, while giving GSK'872 during the reperfusion phase has limited effect on the programmed necrosis of alveolar type II epithelial cells.
[0091] 3.2.4 Immunofluorescence co-staining of pMLKL and macrophage marker CD68 in lung tissue Reference Figure 5 A~C in. Figure 5 A is a typical image of immunofluorescence co-staining of pMLKL and CD68 (macrophage marker) in paraffin sections of rat lung tissue; Figure 5 B in the figure is a statistical diagram of the number of macrophages under high power field (HPF, 400×); Figure 5 C in the figure is a statistical graph showing the ratio of pMLKL fluorescence positive macrophages to the total number of macrophages. Cold ischemia or lung transplantation induced programmed necrosis of macrophages in rat lungs.
[0092] Immunofluorescence co-staining of pMLKL and macrophage marker CD68 from lung tissue ( Figure 5 As shown in Figure A, there was no significant difference in the number of macrophages (CD68 positive) in lung tissues among the sham group (Sham), the cold ischemia group (Only cold ischemia for 18 h) and the lung transplantation group (Cold ischemia for 18 h and reperfusion for 4 h) ( Figure 5 B in the figure indicates that within 4 hours after rat lung transplantation, the macrophages in the lung tissue mainly come from the macrophages resident in the original donor lung, and a small number of macrophages come from the recipient's peripheral blood. Studies have shown that macrophages from peripheral blood infiltrate the lungs only 6 hours after acute lung injury.
[0093] For the left lung of rats with only cold ischemia for 18 h (Only cold ischemia for 18 h -Vehicle), the pMLKL-positive cells were significantly increased compared with the sham group (Sham), and pMLKL and CD68 were significantly co-localized. The pMLKL / CD68 double-positive cells in the left lung of rats in the only cold ischemia for 18 h group were also significantly increased compared with the sham group, indicating that cold ischemia treatment can cause programmed necrosis of macrophages in transplanted lungs. In the only cold ischemia group (Only cold ischemia for 18 h - GSK'872) given with GSK'872, the proportion of pMLKL-positive macrophages was significantly reduced compared with the cold ischemia group (Only cold ischemiafor 18 h -Vehicle) without drug administration, but it did not decrease to the level of the sham group, indicating that adding GSK'872 to the organ preservation solution can significantly reduce the programmed necrosis of macrophages in the lung caused by lung cold ischemia.
[0094] In the left lung of rats undergoing cold ischemia for 18 h and reperfusion for 4 h (Cold ischemia for 18 h and reperfusion for 4 h -Vehicle, i.e., the lung transplantation model group without medication), the number of pMLKL-positive cells was significantly increased compared with that in the sham operation group (Sham), and pMLKL and CD68 were significantly co-localized, indicating that pMLKL was localized in the macrophages in the transplanted lung after lung transplantation modeling.
[0095] The proportion of pMLKL-positive macrophages in the transplanted lungs of rats in the group that was given GSK'872 throughout the whole process (Cold ischemia for 18 h and reperfusion for 4 h -D+R) and the group that was given GSK'872 only during the cold ischemia phase (Cold ischemia for 18 h and reperfusion for 4 h -D) was significantly decreased compared with that in the model group without medication (Cold ischemia for 18 hand reperfusion for 4 h -Vehicle), but did not decrease to the level of the sham operation group. The proportion of pMLKL-positive macrophages in the transplanted lungs of the group that was given GSK'872 only during reperfusion (Cold ischemia for 18 h and reperfusion for 4 h -R) was not significantly different from that in the model group without medication (Cold ischemia for 18 h and reperfusion for4 h -Vehicle) ( Figure 5 C in the figure) indicates that adding GSK'872 to the organ preservation solution can significantly reduce the programmed necrosis of lung macrophages caused by lung transplant injury, while giving GSK'872 during the reperfusion phase has limited effect on the programmed necrosis of lung macrophages.
[0096] 3.3 GSK'872 inhibits the RIP3-dependent NLRP3 inflammasome pathway and NFκB pathway in rat lung transplantation Reference Figure 6 A~F in. Figure 6 A in the figure shows the levels of NLRP3 and NFκB pathway-related proteins in rat lung tissue homogenates detected by WB; Figure 6 B in the figure is WB detection of NLRP3 levels in lung tissue; Figure 6 C in the figure is the phosphorylation level of IκBα in lung tissue detected by WB; Figure 6 D in the figure is ELISA to detect the content of IL-1β in rat transplanted lungs; Figure 6 E in the figure is the ELISA test of serum MPO levels in rats of each group after lung transplantation; Figure 6F in the figure shows the level of N-GSDMD in lung tissue detected by WB. GSK'872 inhibits the activation of NLRP3 and NFκB pathways in rat lung transplantation.
[0097] In addition to the RIP3-dependent programmed necrosis pathway, this study also found that GSK'872 improved acute inflammatory injury in rat lung transplantation by inhibiting the RIP3-dependent NLRP3 inflammasome pathway.
[0098] Proteins from transplanted lung tissue homogenates of rats in each group were extracted 4 h after transplantation for WB detection ( Figure 6 A in the figure shows that the NLRP3 level in the lung transplant model group without drug administration (Vehicle group) was significantly higher than that in the sham operation group, while the NLRP3 level in the transplanted lungs of the group (D group) that was given GSK'872 only during the cold ischemia phase was significantly lower than that in the lung transplant model group without drug administration (Vehicle group), and was reduced to the level of the sham operation group; the NLRP3 level in the other lung transplant groups with drug administration was significantly higher than that in the sham operation group, but there was no significant difference in the NLRP3 level in the transplanted lungs compared with the lung transplant group without drug administration (Vehicle group) ( Figure 6 This suggests that GSK'872 administration during the cold ischemia phase could inhibit the NLRP3 inflammasome pathway in transplanted lungs.
[0099] The levels of N-Gasdermin D (N-GSDMD) in lung tissue of the lung transplantation model group were significantly higher than those in the sham operation group, indicating that the NLRP3 pathway was significantly activated in the transplanted lungs; while the levels of N-GSDMD in the drug-treated groups were significantly lower than those in the lung transplantation model group, and decreased to the level of the sham operation group ( Figure 6 F in Figure 1). This suggests that GSK'872 can inhibit pyroptosis of transplanted lung cells; combined with the expression results of NLRP3, it can be seen that GSK'872 administered during the cold ischemia phase can inhibit cell pyroptosis by inhibiting the NLRP3 inflammasome pathway, while GSK'872 administered during the reperfusion phase may inhibit cell pyroptosis by affecting other signal transduction pathways.
[0100] In addition, the IκBα phosphorylation level in lung tissue of the lung transplant model group was significantly higher than that in the sham operation group. However, only the administration of GSK'872 during the reperfusion phase could significantly reduce the increase in IκBα phosphorylation level caused by transplanted lungs, but it did not drop to the level of the sham operation group ( Figure 6 C). This indicates that GSK'872 administration during the reperfusion phase can inhibit the activation of the NFκB pathway in transplanted lungs.
[0101] ELISA test of tissue homogenate of transplanted lungs of rats in each group 4 hours after transplantation showed that the IL-1β level in the lung transplant model group without drug administration (Vehicle group) was significantly higher than that in the sham operation group, while the administration of GSK'872 throughout the whole process (D+R group) or only during the cold ischemia stage (D group) could significantly reduce the increase of IL-1β level in the lung caused by transplantation, and reduced it to a level that was not significantly different from that in the sham operation group ( Figure 6 D). Since the mature release of IL-1β depends on the activation of the NLRP3 inflammasome pathway, this result further suggests that GSK'872 administration during the cold ischemia phase can inhibit the activation of the NLRP3 inflammasome pathway.
[0102] The MPO levels in the serum of the recipient rats in each group were detected by ELISA. It was found that the MPO concentration in the serum of the rats in the lung transplant modeling group without medication (Vehicle group) and the lung transplant modeling group given GSK'872 throughout the whole process (D+R group) was significantly higher than that in the sham operation group. GSK'872 only given during the reperfusion phase (R group) significantly reduced the increase in serum MPO concentration caused by lung transplantation and reduced it to the level of the sham operation group ( Figure 6 This suggests that administration of GSK'872 during the reperfusion phase can inhibit neutrophil degranulation and release of MPO.
[0103] 3.4 GSK'872 inhibits neutrophil inflammation in rat peripheral blood 3.4.1 Immunofluorescence co-staining of phosphorylated RIP3 and MPO (neutrophil marker protein) was performed using donor lungs with only 18 h of cold ischemia and transplanted lung tissues with 18 h of cold ischemia and 4 h of reperfusion Reference Figure 7 A~B in. Figure 7 A in the figure shows immunofluorescence co-staining of pRIP3 and MPO (neutrophil marker) in paraffin sections of rat lung tissues treated with cold ischemia (donor lung) and cold ischemia-reperfusion (transplanted lung); Figure 7 B is a statistical graph showing the ratio of pRIP3 fluorescence and MPO fluorescence double positive cells to the total MPO positive cells. GSK'872 inhibits the phosphorylation of RIP3 in rat transplanted lung neutrophils.
[0104] Based on the above experimental results, we speculate that the mechanism by which GSK'872 improves rat lung transplant injury during the reperfusion phase involves its inhibition of neutrophil inflammation in the peripheral blood of recipient rats, thereby reducing the damage to the transplanted lung.
[0105] To confirm the above speculation, we used whole experimental samples and in vitro cell experimental samples for detection.
[0106] The results of the overall experimental samples are as follows: Phosphorylated RIP3 and MPO (neutrophil marker protein) were co-stained with immunofluorescence from donor lungs with only cold ischemia for 18 h (Only cold ischemiafor 18 h) and transplanted lung tissues with cold ischemia for 18 h / reperfusion for 4 h (Cold ischemia for 18 h and reperfusion for 4 h). Figure 7 A in the figure shows that there are very few neutrophils in the donor lungs preserved by cold ischemia after perfusion, while there are a large number of neutrophil infiltrations in the lungs of rats that undergo reperfusion after transplantation. It can be seen that the neutrophils in the transplanted lungs mainly come from the peripheral blood of the recipient rats. Previous studies have reported that neutrophils from peripheral blood infiltrate the lungs 2 hours after acute lung injury, which supports our results.
[0107] In the left lungs of rats treated with cold ischemia for 18 h only, the number of pRIP3-positive cells was significantly increased compared with the sham operation group, and pRIP3 and MPO were significantly co-localized. The number of pRIP3 / MPO double-positive cells in the cold ischemia groups was also significantly increased compared with the sham operation group, indicating that cold ischemia alone can induce phosphorylation of RIP3 in neutrophils. The proportion of pRIP3-positive neutrophils in the cold ischemia model group given GSK'872 (GSK'872 group) was significantly lower than that in the cold ischemia model group not given (Vehicle group), but it did not decrease to the level of the sham operation group, indicating that the addition of GSK'872 to the organ preservation solution can significantly reduce the phosphorylation of neutrophil RIP3 induced by lung cold ischemia.
[0108] In the left lung (transplanted lung) of rats treated with cold ischemia for 18 h and reperfusion for 4 h, the number of pRIP3-positive cells was significantly increased compared with that in the sham operation group, and pRIP3 and MPO were significantly co-localized, indicating that lung cold ischemia reperfusion (lung transplantation model) can also induce phosphorylation activation of RIP3 in neutrophils.
[0109] Compared with the unmedicated model group (Vehicle group), the proportion of pRIP3-positive neutrophils in the transplanted lungs of rats that were given GSK'872 throughout the entire process (D+R group) and only during the reperfusion phase (R group) was significantly decreased, but not reduced to the level of the sham operation group. However, the proportion of pRIP3-positive neutrophils in the transplanted lungs of rats that were given GSK'872 only during the cold ischemia phase (D group) was not significantly different from that of the unmedicated model group (Vehicle group). Figure 7B in Figure 1). This indicates that administration of GSK'872 during reperfusion can significantly reduce RIP3 phosphorylation of neutrophils induced by lung transplantation. Combined with the fact that there are very few neutrophils in the lungs after perfusion cold ischemia of the donor lungs before transplantation, it indicates that GSK'872 inhibits RIP3 phosphorylation of neutrophils in the peripheral blood of recipient rats as one of its main mechanisms of action.
[0110] 3.4.2 Detection of MPO levels in cell supernatant by ELISA Reference Figure 8 A~I in. Figure 8 A in the figure shows that DAPI staining shows that after LPS stimulation, the neutrophil nuclei are fragmented and connected to each other to form NETs. GSK'872 (50 μM) pretreatment (1 h) can reduce the LPS-induced neutrophil NETs formation. Figure 8 B in the figure is the scoring and statistical graph of NETs formation of each group of rat peripheral blood neutrophils; Figure 8 C in the figure is the concentration of MPO in the cell supernatant of each group of rat peripheral blood neutrophils detected by ELISA and the statistical graph is drawn; Figure 8 D in the figure is a typical WB image of neutrophils in rat peripheral blood; Figure 8 E~I in the figure are the statistical charts of pRIP3, NLRP3, GSDMD, N-GSDMD, and pIκBα levels in peripheral blood neutrophils of rats detected by WB. GSK'872 inhibits inflammation of peripheral blood neutrophils in rats.
[0111] The results of the in vitro cell samples are as follows: We extracted neutrophils from the peripheral blood of rats, activated the neutrophils with lipopolysaccharide (LPS), observed the formation of neutrophil extracellular traps (NETs) under a microscope, and detected the level of MPO in the cell supernatant with ELISA. We found that the neutrophils given GSK'872 alone had no difference in NETs formation and MPO levels in the cell supernatant compared with the Control group; after LPS stimulation, neutrophils formed a large number of NETs, and the MPO level in the supernatant increased significantly; GSK'872 administration can significantly reduce the level of NETs formed by LPS-induced neutrophils, but it did not drop to the level of the Control group ( Figure 8 A, B in the figure); and it can significantly reduce the increase of MPO level in the cell supernatant induced by LPS, and reduce it to the level of the Control group ( Figure 8 C). This suggests that GSK'872 can inhibit neutrophil inflammation.
[0112] So, by what mechanism does GSK'872 inhibit neutrophil inflammation? We first tested the effect of GSK'872 on neutrophil programmed necrosis. We used isolated and purified rat peripheral blood neutrophils, treated them with LPS (20 μg / mL) for 2 h, and then lysed the cells to extract proteins for WB detection ( Figure 8 D in the figure shows that the single administration of GSK'872 can significantly reduce the phosphorylation level of RIP3 in neutrophils compared with the control group; after LPS stimulation, the phosphorylation level of RIP3 in neutrophils was significantly increased compared with the control group, while the administration of GSK'872 can significantly reduce the increase in the phosphorylation level of RIP3 in neutrophils induced by LPS stimulation and reduce it to the level of the control group ( Figure 8 E in the figure); however, the levels of programmed necrosis marker proteins MLKL and pMLKL in neutrophils are extremely low ( Figure 8 This suggests that GSK'872 may regulate neutrophil inflammation through pathways other than RIP3-dependent programmed necrosis in neutrophils.
[0113] Considering that the generation of N-GSDMD after inflammasome activation is closely related to the release of IL-1β by neutrophils, we speculated that the generation of N-GSDMD and the release of MPO in rat peripheral blood neutrophils are related to inflammasome activation, so this study used WB to detect the effect of GSK'872 on the neutrophil inflammasome pathway. We found that there was no significant difference in the NLRP3 level of neutrophils in the control group and the LPS-only stimulation group, but GSK'872 alone could reduce the level of NLRP3 in neutrophils ( Figure 8 This suggests that although LPS-activated neutrophils do not affect the protein expression level of NLRP3, GSK'872 can regulate neutrophils by inhibiting the NLRP3 inflammasome pathway.
[0114] WB detection further found that LPS had a tendency to induce an increase in the level of GSDMD in neutrophils, but there was no statistical difference compared with the Control ( Figure 8 D in the figure); however, the administration of GSK'872 alone can reduce the level of GSDMD in neutrophils, which is lower than that in the Control group; after LPS stimulation, the administration of GSK'872 resulted in a significantly lower level of GSDMD in neutrophils than that in the LPS group and the Control group ( Figure 8 in G).
[0115] Similarly, the single administration of GSK'872 can significantly reduce the level of cellular N-GSDMD and lower it to the level of the Control group; the administration of LPS can induce a significant increase in the level of N-GSDMD in neutrophils; the level of N-GSDMD in neutrophils in the LPS-stimulated group given GSK'872 was significantly lower than that in the LPS-stimulated group, and dropped below the level of the Control group ( Figure 8 This indicates that GSK'872 not only down-regulates the level of neutrophil GSDMD, but also inhibits the cleavage of GSDMD to generate N-GSDMD, thereby inhibiting the release of MPO, which is dependent on N-GSDMD, in neutrophil degranulation.
[0116] So, by what mechanism does GSK'872 affect the baseline expression of molecules such as NLRP3 and GSDMD in neutrophils? We detected changes in the NFκB pathway, a classic transcriptional regulator associated with inflammation. WB results showed that there was no significant difference in the level of phosphorylated IκBα between the Control group and the group given GSK'872 alone. After LPS administration, the level of phosphorylated IκBα in the group not given GSK'872 was significantly higher than that in the Control group. However, after GSK'872 administration, the level of phosphorylated IκBα in neutrophils decreased compared with that in the group given only LPS, and decreased to the level of the Control group ( Figure 8 I in the figure). Combined with the results of previous studies suggesting that inhibition of NFκB can inhibit GSDMD transcription, we believe that GSK'872 inhibits LPS-induced neutrophil inflammation by reducing NLRP3 and GSDMD transcriptional expression by inhibiting NFκB pathway activation.
[0117] IV. Conclusion In summary, GSK'872 has an improving effect on rat lung transplant injury, and has different mechanisms of action when administered at different times: GSK'872 administered during the cold ischemia stage can inhibit inflammation mediated by pathways such as programmed necrosis mediated by RIP3 phosphorylation in lung macrophages, thereby alleviating ischemia-reperfusion injury of transplanted lungs; GSK'872 administered during the reperfusion stage can inhibit RIP3 phosphorylation to inhibit the neutrophil NLRP3 inflammasome pathway and NFκB pathway to alleviate peripheral blood neutrophil inflammation in recipient rats, thereby indirectly protecting against lung transplant injury.
[0118] The above description is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and modifications without departing from the concept of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. Use of a RIP3 inhibitor in the preparation of a pharmaceutical composition for alleviating ischemia-reperfusion injury in lung transplantation.
2. The use according to claim 1, Features: The RIP3 inhibitor is GSK'872.
3. Use of GSK'872 in the preparation of a pharmaceutical composition for inhibiting inflammation mediated by the programmed cell necrosis pathway mediated by RIP3 phosphorylation in pulmonary macrophages.
4. Use of GSK'872 in the preparation of a pharmaceutical composition for alleviating peripheral blood neutrophil inflammation by inhibiting RIP3 phosphorylation to inhibit the neutrophil NLRP3 inflammasome pathway and NFκB pathway.
5. A pharmaceutical composition for alleviating ischemia-reperfusion injury in lung transplantation, Features: The pharmaceutical composition comprises an effective amount of GSK'872 and a pharmaceutically acceptable excipient.
6. A pharmaceutical composition for reducing neutrophilic inflammation, Features: The pharmaceutical composition comprises an effective amount of GSK'872 and a pharmaceutically acceptable excipient.
Citation Information
Patent Citations
Composition for preventing or treating immune disease, comprising RIPK inhibitor as active ingredient
WO2017022962A1
Cited By
Application of GSK-872 in preparation of medicine for treating traumatic optic neuropathy
CN119185311A
